Novartis blueprints $36M vaccine research lab in NC

Novartis ($NVS) has blueprinted plans for a $36 million vaccine research lab in Holly Springs, NC, and plans to fill about 100 high-paying jobs to staff the addition.

The expansion follows the construction of Novartis' $600 million vaccine manufacturing plant, which opened last year. This new facility will include vaccine manufacturing capacity to produce experimental vaccines for research studies.

Novartis, which landed a 167-acre site in Holly Springs, is creating a vaccine research and manufacturing hub in the area alongside Merck ($MRK) and Pfizer ($PFE).

- here's the story from the News & Observer

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.